CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $39.63M, above the global median of $16.24M
- FinancialsAltman Z-Score 10.29: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.85%Below 5Y avg (1.62%)
Annual Rate
CNY 0.50Paid annual
Payout Ratio
57.4%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
6.53BCNY970.00M · vs all stocks (USD)
Trailing P/E
27.99xvs Biotechnology peers
Revenue (TTM)
1.20BCNY178.15M · vs all stocks (USD)
Profit Margin
18.89%vs Biotechnology peers
Beta
0.3870xvs all stocks
52-Week Change
-31.73%vs all stocks
Market Capitalization
6.53BCNY970.00M · vs all stocks (USD)
Enterprise Value
5.30BCNY787.85M · vs all stocks (USD)
Trailing P/E
27.99xvs Biotechnology peers
Forward P/E
7.96xvs Biotechnology peers
Price to Sales (TTM)
5.28xvs Biotechnology peers
Price to Book (MRQ)
1.78xvs Biotechnology peers
Enterprise to Revenue
4.42xvs Biotechnology peers
Enterprise to EBITDA
15.95xvs Biotechnology peers
Gross Margin
90.98%vs Biotechnology peers
Profit Margin
18.89%vs Biotechnology peers
Operating Margin
17.52%vs Biotechnology peers
Return on Assets (TTM)
4.13%vs Biotechnology peers
Return on Equity (TTM)
6.44%vs Biotechnology peers
Revenue (TTM)
1.20BCNY178.15M · vs all stocks (USD)
Revenue per Share (TTM)
9.23CNYUpdated Aug 20, 2026Quarterly Revenue Growth
25.00%vs Biotechnology peers
Gross Profit (TTM)
1.09BCNY162.00M · vs all stocks (USD)
EBITDA (TTM)
225.15MCNY33.44M · vs all stocks (USD)
Net Income (TTM)
226.55MCNY33.65M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
32.10%vs Biotechnology peers
Operating Cash Flow (TTM)
417.27MCNY61.97M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
266.82MCNY39.63M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.85%vs all stocks
5-Year Average Dividend Yield
1.62%vs all stocks
Payout Ratio
57.36%vs Biotechnology peers
Revenue
1.17BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
92.80MCNYFY2025 · Dec 31, 2025Gross Profit
1.07BCNYFY2025 · Dec 31, 2025Operating Income
273.12MCNY40.56M · vs all stocks (USD)
Pre-tax Income
259.74MCNYFY2025 · Dec 31, 2025Income Tax Expense
39.85MCNYFY2025 · Dec 31, 2025Net Income
219.90MCNYFY2025 · Dec 31, 2025EBIT
263.42MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
363.37MCNYFY2025 · Dec 31, 2025Research & Development
118.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
556.65MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.15MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.68MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.69CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.69CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
129.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
129.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
219.90MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
322.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
252.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.14BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
219.90MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.39MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
64.31MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
23.21MCNYFY2025 · Dec 31, 2025Capital Expenditures
-70.72MCNYFY2025 · Dec 31, 2025Purchase of Investments
-810.00MCNYFY2025 · Dec 31, 2025Sale of Investments
1.03BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
147.35MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
179.79MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-226.78MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-136.43MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-183.42MCNYFY2025 · Dec 31, 2025Shares Outstanding
129.95MSharesUpdated Aug 20, 2026Float Shares
86.81MSharesUpdated Aug 20, 2026% Held by Insiders
33.02%vs all stocks
% Held by Institutions
9.71%vs all stocks
Total Cash (MRQ)
1.06BCNY156.71M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.12CNYUpdated Aug 20, 2026Total Debt (MRQ)
30.11MCNY4.47M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0084xvs Biotechnology peers
Current Ratio (MRQ)
7.89xvs Biotechnology peers
Book Value per Share (MRQ)
27.43CNYUpdated Aug 20, 2026Total Assets
4.01BCNY595.53M · vs all stocks (USD)
Total Current Assets
2.52BCNYFY2025 · Dec 31, 2025Total Liabilities
472.31MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
32.99MCNYFY2025 · Dec 31, 2025Total Current Liabilities
439.32MCNYFY2025 · Dec 31, 2025Cash
1.15BCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.15BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.23BCNYFY2025 · Dec 31, 2025Inventory
140.81MCNYFY2025 · Dec 31, 2025Accounts Payable
2.95MCNYFY2025 · Dec 31, 2025Short-term Debt
139.90MCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.06KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
24.88MCNYFY2025 · Dec 31, 2025Common Stock (Book)
129.95MCNYFY2025 · Dec 31, 2025Retained Earnings
2.48BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.54BCNY525.38M · vs all stocks (USD)
52-Week Low
42.31CNYUpdated Aug 20, 202652-Week High
87.52CNYUpdated Aug 20, 202652-Week Change
-31.73%vs all stocks
Beta
0.3870xvs all stocks
50-Day MA
46.39CNYUpdated Aug 20, 2026200-Day MA
61.86CNYUpdated Aug 20, 2026Avg 10-Day Volume
2.57MSharesUpdated Aug 20, 2026Avg 30-Day Volume
2.57MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.74CNYUpdated Aug 20, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.25Receivables vs revenue divergence: 2.33
Financial Health
Altman Z-Score 10.29: safe zoneNotable
Altman Z-Score: 10.29
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $39.63M, above the global median of $16.24MNotable
Levered free cash flow (USD): 39,628,619.685Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Ghcl Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedCash Backing With OCF Coverage And Cash Near Total Debt
Fortune Electric Co., Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedCash Backing With OCF Coverage And Cash Near Total Debt
Allied Supreme Corporation
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityCash Backing With OCF Coverage And Cash Near Total Debt